Suche senden
Hochladen
Ppt chapter 28
•
Als PPT, PDF herunterladen
•
4 gefällt mir
•
2,413 views
S
stanbridge
Folgen
Melden
Teilen
Melden
Teilen
1 von 27
Jetzt herunterladen
Empfohlen
Ppt chapter 26
Ppt chapter 26
stanbridge
Ppt chapter 40
Ppt chapter 40
stanbridge
Ppt chapter 29
Ppt chapter 29
stanbridge
Ppt chapter 42
Ppt chapter 42
stanbridge
Ppt chapter 16
Ppt chapter 16
stanbridge
Ppt chapter 43
Ppt chapter 43
stanbridge
Ppt chapter 45
Ppt chapter 45
stanbridge
Ppt chapter 31-1
Ppt chapter 31-1
stanbridge
Empfohlen
Ppt chapter 26
Ppt chapter 26
stanbridge
Ppt chapter 40
Ppt chapter 40
stanbridge
Ppt chapter 29
Ppt chapter 29
stanbridge
Ppt chapter 42
Ppt chapter 42
stanbridge
Ppt chapter 16
Ppt chapter 16
stanbridge
Ppt chapter 43
Ppt chapter 43
stanbridge
Ppt chapter 45
Ppt chapter 45
stanbridge
Ppt chapter 31-1
Ppt chapter 31-1
stanbridge
Ppt chapter 41
Ppt chapter 41
stanbridge
Ppt chapter 49
Ppt chapter 49
stanbridge
Ppt chapter 20-1
Ppt chapter 20-1
stanbridge
Ppt chapter 42
Ppt chapter 42
stanbridge
Ppt chapter 33
Ppt chapter 33
stanbridge
Ppt chapter 52-1
Ppt chapter 52-1
stanbridge
Ppt chapter 44
Ppt chapter 44
stanbridge
Ppt chapter 37
Ppt chapter 37
stanbridge
Ppt chapter 26-1
Ppt chapter 26-1
stanbridge
Ppt chapter 39
Ppt chapter 39
stanbridge
Ppt chapter 36-1
Ppt chapter 36-1
stanbridge
Ppt chapter 57
Ppt chapter 57
stanbridge
Ppt chapter 30-1
Ppt chapter 30-1
stanbridge
Ppt chapter 03
Ppt chapter 03
stanbridge
Ppt chapter 46
Ppt chapter 46
stanbridge
Ppt chapter 51-1
Ppt chapter 51-1
stanbridge
Ppt chapter 25
Ppt chapter 25
stanbridge
Ppt chapter 32
Ppt chapter 32
stanbridge
Ppt chapter 59
Ppt chapter 59
stanbridge
Ppt chapter 39
Ppt chapter 39
stanbridge
Ppt chapter 22
Ppt chapter 22
stanbridge
Ppt chapter 18
Ppt chapter 18
stanbridge
Weitere ähnliche Inhalte
Was ist angesagt?
Ppt chapter 41
Ppt chapter 41
stanbridge
Ppt chapter 49
Ppt chapter 49
stanbridge
Ppt chapter 20-1
Ppt chapter 20-1
stanbridge
Ppt chapter 42
Ppt chapter 42
stanbridge
Ppt chapter 33
Ppt chapter 33
stanbridge
Ppt chapter 52-1
Ppt chapter 52-1
stanbridge
Ppt chapter 44
Ppt chapter 44
stanbridge
Ppt chapter 37
Ppt chapter 37
stanbridge
Ppt chapter 26-1
Ppt chapter 26-1
stanbridge
Ppt chapter 39
Ppt chapter 39
stanbridge
Ppt chapter 36-1
Ppt chapter 36-1
stanbridge
Ppt chapter 57
Ppt chapter 57
stanbridge
Ppt chapter 30-1
Ppt chapter 30-1
stanbridge
Ppt chapter 03
Ppt chapter 03
stanbridge
Ppt chapter 46
Ppt chapter 46
stanbridge
Ppt chapter 51-1
Ppt chapter 51-1
stanbridge
Ppt chapter 25
Ppt chapter 25
stanbridge
Ppt chapter 32
Ppt chapter 32
stanbridge
Ppt chapter 59
Ppt chapter 59
stanbridge
Ppt chapter 39
Ppt chapter 39
stanbridge
Was ist angesagt?
(20)
Ppt chapter 41
Ppt chapter 41
Ppt chapter 49
Ppt chapter 49
Ppt chapter 20-1
Ppt chapter 20-1
Ppt chapter 42
Ppt chapter 42
Ppt chapter 33
Ppt chapter 33
Ppt chapter 52-1
Ppt chapter 52-1
Ppt chapter 44
Ppt chapter 44
Ppt chapter 37
Ppt chapter 37
Ppt chapter 26-1
Ppt chapter 26-1
Ppt chapter 39
Ppt chapter 39
Ppt chapter 36-1
Ppt chapter 36-1
Ppt chapter 57
Ppt chapter 57
Ppt chapter 30-1
Ppt chapter 30-1
Ppt chapter 03
Ppt chapter 03
Ppt chapter 46
Ppt chapter 46
Ppt chapter 51-1
Ppt chapter 51-1
Ppt chapter 25
Ppt chapter 25
Ppt chapter 32
Ppt chapter 32
Ppt chapter 59
Ppt chapter 59
Ppt chapter 39
Ppt chapter 39
Andere mochten auch
Ppt chapter 22
Ppt chapter 22
stanbridge
Ppt chapter 18
Ppt chapter 18
stanbridge
Ppt chapter 31
Ppt chapter 31
stanbridge
Ppt chapter 30
Ppt chapter 30
stanbridge
Ppt chapter 52
Ppt chapter 52
stanbridge
Ppt chapter 21
Ppt chapter 21
stanbridge
Ppt chapter 20
Ppt chapter 20
stanbridge
Ppt chapter 34
Ppt chapter 34
stanbridge
Ppt chapter 35
Ppt chapter 35
stanbridge
Ppt chapter 51
Ppt chapter 51
stanbridge
Ppt chapter 36
Ppt chapter 36
stanbridge
Ppt chapter 50
Ppt chapter 50
stanbridge
Ppt chapter 45
Ppt chapter 45
stanbridge
Chapter 23 ppt
Chapter 23 ppt
stanbridge
Ppt chapter 50-1
Ppt chapter 50-1
stanbridge
Ppt chapter 21
Ppt chapter 21
stanbridge
Chapter027
Chapter027
stanbridge
Chapter 35 HIV Presentation
Chapter 35 HIV Presentation
Florida State College at Jacksonville
Andere mochten auch
(18)
Ppt chapter 22
Ppt chapter 22
Ppt chapter 18
Ppt chapter 18
Ppt chapter 31
Ppt chapter 31
Ppt chapter 30
Ppt chapter 30
Ppt chapter 52
Ppt chapter 52
Ppt chapter 21
Ppt chapter 21
Ppt chapter 20
Ppt chapter 20
Ppt chapter 34
Ppt chapter 34
Ppt chapter 35
Ppt chapter 35
Ppt chapter 51
Ppt chapter 51
Ppt chapter 36
Ppt chapter 36
Ppt chapter 50
Ppt chapter 50
Ppt chapter 45
Ppt chapter 45
Chapter 23 ppt
Chapter 23 ppt
Ppt chapter 50-1
Ppt chapter 50-1
Ppt chapter 21
Ppt chapter 21
Chapter027
Chapter027
Chapter 35 HIV Presentation
Chapter 35 HIV Presentation
Ähnlich wie Ppt chapter 28
Ppt chapter 47
Ppt chapter 47
stanbridge
Lipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugs
Urmila Aswar
Ppt chapter 08-1
Ppt chapter 08-1
stanbridge
Hypolipidemic drugs.ppt
Hypolipidemic drugs.ppt
Urmila Aswar
Ppt chapter 38-1
Ppt chapter 38-1
stanbridge
Hyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemia
akbar siddiq
Ppt chapter 20
Ppt chapter 20
stanbridge
Hyperlipidemia
Hyperlipidemia
Juliya Susan Reji
Ppt chapter 10-1
Ppt chapter 10-1
stanbridge
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
Dr Sachin P. Padole
Ppt chapter 38
Ppt chapter 38
stanbridge
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
MukundGurav
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Dr. Baqir Raza Naqvi
Ppt chapter 37
Ppt chapter 37
stanbridge
Nutrition management of liver condition.pptx
Nutrition management of liver condition.pptx
Happychifunda
Hyperlipidemia pharmacotherapy
Hyperlipidemia pharmacotherapy
Urvi Kolhatkar
Management of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdf
HemanhuelCTankxes
Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing
Dr Resu Neha Reddy
Case presentation
Case presentation
Deependra Shrestha
Hyperlipidemia
Hyperlipidemia
saleemslide
Ähnlich wie Ppt chapter 28
(20)
Ppt chapter 47
Ppt chapter 47
Lipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugs
Ppt chapter 08-1
Ppt chapter 08-1
Hypolipidemic drugs.ppt
Hypolipidemic drugs.ppt
Ppt chapter 38-1
Ppt chapter 38-1
Hyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemia
Ppt chapter 20
Ppt chapter 20
Hyperlipidemia
Hyperlipidemia
Ppt chapter 10-1
Ppt chapter 10-1
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
Ppt chapter 38
Ppt chapter 38
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Ppt chapter 37
Ppt chapter 37
Nutrition management of liver condition.pptx
Nutrition management of liver condition.pptx
Hyperlipidemia pharmacotherapy
Hyperlipidemia pharmacotherapy
Management of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdf
Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing
Case presentation
Case presentation
Hyperlipidemia
Hyperlipidemia
Mehr von stanbridge
Micro Lab 3 Lecture
Micro Lab 3 Lecture
stanbridge
Creating a poster v2
Creating a poster v2
stanbridge
Creating a poster
Creating a poster
stanbridge
Sample poster
Sample poster
stanbridge
OT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
stanbridge
Ot5101 005 week 5
Ot5101 005 week 5
stanbridge
Ot5101 005 week4
Ot5101 005 week4
stanbridge
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
stanbridge
Ch 5 developmental stages of the learner
Ch 5 developmental stages of the learner
stanbridge
OT 5101 week2 theory policy
OT 5101 week2 theory policy
stanbridge
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
stanbridge
Ot5101 week1
Ot5101 week1
stanbridge
NUR 304 Chapter005
NUR 304 Chapter005
stanbridge
NUR 3043 Chapter007
NUR 3043 Chapter007
stanbridge
NUR 3043 Chapter006
NUR 3043 Chapter006
stanbridge
NUR 3043 Chapter004
NUR 3043 Chapter004
stanbridge
3043 Chapter009
3043 Chapter009
stanbridge
3043 Chapter008
3043 Chapter008
stanbridge
Melnyk ppt chapter_21
Melnyk ppt chapter_21
stanbridge
Melnyk ppt chapter_22
Melnyk ppt chapter_22
stanbridge
Mehr von stanbridge
(20)
Micro Lab 3 Lecture
Micro Lab 3 Lecture
Creating a poster v2
Creating a poster v2
Creating a poster
Creating a poster
Sample poster
Sample poster
OT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
Ot5101 005 week 5
Ot5101 005 week 5
Ot5101 005 week4
Ot5101 005 week4
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
Ch 5 developmental stages of the learner
Ch 5 developmental stages of the learner
OT 5101 week2 theory policy
OT 5101 week2 theory policy
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
Ot5101 week1
Ot5101 week1
NUR 304 Chapter005
NUR 304 Chapter005
NUR 3043 Chapter007
NUR 3043 Chapter007
NUR 3043 Chapter006
NUR 3043 Chapter006
NUR 3043 Chapter004
NUR 3043 Chapter004
3043 Chapter009
3043 Chapter009
3043 Chapter008
3043 Chapter008
Melnyk ppt chapter_21
Melnyk ppt chapter_21
Melnyk ppt chapter_22
Melnyk ppt chapter_22
Ppt chapter 28
1.
Chapter 28 Drugs
Affecting Lipid Levels Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
2.
Copyright © 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins Question • What is the optimal low-density lipoprotein (LDL) level? – A. 200 mg/dL – B. 160 mg/dL – C. 130 mg/dL – D. 100 mg/dL
3.
Copyright © 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • D. 100 mg/dL • Rationale: 100 mg/dL is the optimal LDL level according to NCEP. Some newer data are suggesting that the LDL should be even lower than that in patients with risk factors for myocardial infarctions and strokes.
4.
Physiology • Serum
lipids are fats found in the bloodstream. • These lipids include cholesterol, cholesterol esters (compounds), phospholipids, and triglycerides. • They are transported in the blood as part of large molecules called lipoproteins. • Cholesterol is a soft, waxy substance found among the lipids in the bloodstream and in all of the body’s cells. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
5.
Physiology (cont.) •
The body, mostly in the liver, produces essentially all of the cholesterol needed for normal functioning—about 1,000 mg a day. • Cholesterol plays a role in forming cell membranes, some hormones, and other needed tissues. • LDL is the major cholesterol carrier in the blood. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
6.
Pathophysiology • Hyperlipidemia
is an elevation of blood lipid levels. • Hyperlipidemia is considered a risk factor for the following disorders: atherosclerosis, coronary artery disease, and thromboses. • When the amount of cholesterol within cells builds up, the number of these receptors on cell surfaces is reduced, preventing all of the lipids from entering the cells. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
7.
Pathophysiology (cont.) •
Patients with narrowed arteries from atherosclerotic cardiovascular disease are more likely to have hypertension. • Ideal cholesterol levels: – Total cholesterol: less than 200 mg/dL – LDL: 100 mg/dL – HDL: 40 to 59 mg/dL Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
8.
Lifestyle and Reduction
of Low-Density Lipoprotein Levels • The NCEP ATP III recommends a multipronged approach in reducing LDL levels. • They title this approach therapeutic lifestyle changes. • These lifestyle changes include: – Diet – Weight loss – Increased physical activity Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
9.
Antihyperlipidemics Copyright ©
2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
10.
Statins • Statins
lower blood cholesterol levels and thus decrease the uptake of modified lipoproteins by vascular cells. • Statin therapy can lower LDL cholesterol by 20% to 55% when given at their maximum recommended dose. • Statins also raise HDL levels between 5% and 15% and lower triglycerides between 7% and 33%. • In addition, evidence exists that statins work in other ways beside lowering cholesterol levels to decrease the occurrence of cardiovascular events. • Prototype drug: lovastatin (Mevacor) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
11.
Lovastatin: Core Drug
Knowledge • Pharmacotherapeutics – Used for primary hypercholesterolemia and combined hyperlipidemia • Pharmacokinetics – High first-pass effect. Highly protein bound. Excreted primarily through the GI tract • Pharmacodynamics – Competitively inhibits HMG-CoA reductase, which is the enzyme that catalyzes the early rate-limiting step in cholesterol biosynthesis Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
12.
Lovastatin: Core Drug
Knowledge (cont.) • Contraindications and precautions – Active liver disease and pregnancy • Adverse effects – Muscle and joint aches, weakness, cramps, muscle damage, liver damage, and rhabdomyolysis • Drug interactions – Itraconazole, erythromycin, and grapefruit juice Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
13.
Lovastatin: Core Patient
Variables • Health status – Assess cholesterol levels and past medical history. • Life span and gender – Pregnancy category X; assess age of the patient • Lifestyle, diet, and habits – Treat elevated cholesterol with diet and exercise first. • Environment – Assess environment where drug will be given. • Culture and inherited traits – Explore cultural dietary practices. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
14.
Lovastatin: Nursing Diagnoses
and Outcomes • Risk for Injury related to elevated blood lipid levels – Desired outcome: The patient’s blood lipid levels will be controlled without the patient’s sustaining an injury. • Risk for Injury to skeletal muscles related to adverse effects of drug therapy – Desired outcome: The patient will not incur serious skeletal muscle injury while on drug therapy. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
15.
Lovastatin: Nursing Diagnoses
and Outcomes (cont.) • Risk for Injury to liver function related to adverse effects of drug therapy – Desired outcome: The patient will not incur serious liver injury while on drug therapy. • Risk for Altered Nutrition: Less than Body Requirements related to adverse effects of drug therapy – Desired outcome: The patient will not have GI adverse effects serious enough to alter meeting the body’s nutritional needs. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
16.
Lovastatin: Planning and
Interventions • Maximizing therapeutic effects – Most effective when administered in the evening – Immediate-release administered after evening meal – Extended-release administered at bedtime • Minimizing adverse effects – Liver function test (AST and ALT) results should be monitored before starting therapy. – Evaluate the patient carefully for muscle soreness, tenderness, or pain and CK levels. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
17.
Lovastatin: Teaching, Assessment,
and Evaluations • Patient and family education – Stress the importance of following a low-cholesterol and low-saturated-fat diet. – Instruct patients to report any unexplained muscle pain, tenderness, or weakness. – Photosensitivity may occur. • Ongoing assessment and evaluation – The patient should have liver function tests and CK measurement performed periodically throughout drug therapy. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
18.
Copyright © 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Lovastatin is metabolized by which of the following process/system? – A. CYP3A4 – B. 2D6 – C. C121 – D. No process is needed for metabolism.
19.
Copyright © 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • A. CYP3A4 • Rationale: Lovastatin is metabolism by CYP3A4.
20.
Drugs Closely Related
to Lovastatin • Atorvastatin (Lipitor), fluvastatin (Lescol), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor) • All work similarly to lower LDL cholesterol and have similar adverse effects. • Pravastatin differs from the prototype lovastatin because it is not metabolized via the P-450 system and thus does not produce the drug interactions of lovastatin. • Fluvastatin is primarily metabolized via a different isoenzyme pathway. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
21.
Statin Therapy Copyright
© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
22.
Drugs Significantly Different
from Lovastatin: Fibric Acid Derivatives • These drugs lower triglyceride levels and increase HDL cholesterol. • These drugs can reduce triglyceride levels between 35% and 53%. • Effects on LDL cholesterol may be either to lower it between 6% and 20% or to raise it slightly. • Although in certain patients these drugs may be used alone, most frequently they are used in combination with statins. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
23.
Drugs Significantly Different
from Lovastatin: Fibric Acid Derivatives (cont.) • The combined used of a fibrate and a moderate-dose statin carries a somewhat increased risk of myopathy. • Contraindications include hepatic or severe renal dysfunction, including primary biliary cirrhosis, preexisting gallbladder disease, or hypersensitivity. • Serious adverse effects include abnormal liver function tests, rhabdomyolysis, and hyperglycemia. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
24.
Drugs Significantly Different
from Lovastatin: Cholesterol Absorption Inhibitors • Ezetimibe (Zetia) is an antilipid drug that is used to treat hypercholesterolemia. • Its pediatric use is restricted to children older than 10 years of age with familial homozygous hypercholesterolemia. • It is given orally once daily either as monotherapy or in combination therapy with a statin. • It localizes and appears to act at the brush border of the small intestine, where it inhibits the absorption of cholesterol. • Ezetimibe decreases LDL about 17% but has no effect on HDL or triglycerides. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
25.
Drugs Significantly Different
from Lovastatin: Nicotinic Acid • Nicotinic acid (niacin or vitamin B3) is used to treat hyperlipidemia. • Nicotinic acid reduces levels of triglycerides and LDL cholesterol levels and raises levels of HDL cholesterol. • Triglycerides and VLDL levels are reduced by 25% to 30% in 1 to 4 days. LDL level reductions may be seen in 5 to 7 days, with the maximal effect seen in 3 to 5 weeks. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
26.
Drugs Significantly Different
from Lovastatin: Nicotinic Acid (cont.) • Contraindications to its use include hepatic dysfunction, active peptic ulcer, severe hypotension, and hemorrhaging. • The newer sustained-release forms of nicotinic acid have fewer adverse effects. • These larger doses produce peripheral vasodilation, mostly in the cutaneous vessels of the face, neck, and chest. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
27.
Drugs Significantly Different
from Lovastatin: Bile Acid Sequestrants • The bile acid sequestrants cholestyramine (LoCholest, Questran, Prevalite) and colestipol (Colestid) are used to reduce elevated serum cholesterol levels in patients with primary hypercholesterolemia who have not responded to other drug therapy. • Bile acid sequestrants are not absorbed orally but work in the GI tract. • The reduction in LDLs is apparent in 4 to 7 days and ranges between 15% and 30%. • Bile acid sequestrants promote the oxidation of cholesterol to bile acids. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Jetzt herunterladen